MORGANTOWN, W.Va. – West Virginia Attorney General Patrick Morrisey filed suit against more than two dozen generic drug manufacturers, including Mylan Pharmaceuticals, alleging the companies and 10 senior executives conspired to unlawfully increase prices on 80 topical prescriptions.
The products involved account for billions of dollars in sales and include generic drugs common to many medicine cabinets, such as creams, gels, lotions, ointments, shampoos and solutions.
“Those who manipulate prices and reduce competition increase the financial burden on families across West Virginia,” Attorney General Morrisey said. “Generic drugs are a key aspect of affordable healthcare, and alleged actions such as these selfishly undermine the efforts of so many to keep prices affordable for those in desperate need of prescription drugs. Bad actors must be held accountable.”
The lawsuit was brought by 51 attorneys general and targets generic drugmakers like Taro, Perrigo, and Fougera (now Sandoz), along with Mylan Pharmaceuticals, 22 other corporate entities and 10 individual defendants.
The lawsuit accuses the entities and executives of entering into unlawful agreements to minimize competition and raise prices on dozens of topical products. The lawsuit alleges longstanding agreements among manufacturers to ensure a “fair share” of the market for each competitor and prevent “price erosion” due to competition.
It is estimated that Taro, Perrigo and Fougera accounted for nearly two-thirds of all generic topical products prescribed nationwide from 2007 to 2014.
Morrisey says there are several cooperating witnesses, more than 20 million documents and millions of phone records, including call data and contact information for more than 600 sales and pricing individuals in the generics industry.
The evidence includes a two-volume notebook from a witness describing the man’s discussions with competitors and internal meetings over a period of several years.
The lawsuit, filed Wednesday in the U.S. District Court for the District of Connecticut, seeks damages, civil penalties and court action to restore competition to the generic drug market.